At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 22,439 enrolled
Drug / intervention
Zoster Vaccine, Live (Zostavax™) +1 morebiological
Likely dose
Zoster Vaccine, Live (Zostavax™) 0.65 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age
In Brief
A Phase 3 clinical trial evaluating Zoster Vaccine, Live (Zostavax™) and Comparator: Placebo for Shingles. Completed, enrolled 22,439 participants.
Detailed Summary
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShingles
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionJan 2010
TodayJul 2026
First PostedSep 24, 2007
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.8 years ago
Interventions
Zoster Vaccine, Live (Zostavax™)biological
A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
Comparator: Placebobiological
A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.